<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561908</url>
  </required_header>
  <id_info>
    <org_study_id>2020-5</org_study_id>
    <nct_id>NCT04561908</nct_id>
  </id_info>
  <brief_title>Transcatheter Microguidewire Drilling for Transseptal Left Atrial Access</brief_title>
  <acronym>TMD</acronym>
  <official_title>Transcatheter Microguidewire Drilling (TMD) for Transseptal Left Atrial Access: First-in-human Use Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the safety and efficacy of transcatheter microguidewire&#xD;
      drilling (TMD) for transseptal left atrial access in patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the widespread application and decades of experience, Brockenbrough-needle&#xD;
      transseptal puncture still risks cardiac perforations and secondary pericardial&#xD;
      effusion/tamponade, especially in patients with abnormal atrial septal morphology. To&#xD;
      facilitate atrial septal crossing, different methods and devices have been developed,&#xD;
      including radiofrequency energy, excimer laser, SafeSept wire and so on. However, these are&#xD;
      still limited by availability and cost, and the advantages might be further offset by the&#xD;
      potential risks. In addition, these methods are performed mainly with the linear insertion&#xD;
      technique, which might result in less forward-force to penetrate atrial septum and&#xD;
      displacement of needle-tip. Therefore, it is necessary to develop a safe, available and&#xD;
      low-cost transseptal procedure for these patients.&#xD;
&#xD;
      In this study, the hard-end of 0.014-inch microguidewire is used to drill through atrial&#xD;
      septum through a 6F-guidecatheter. Over the fixed microguidewire, a 3.0 or 3.5-mm balloon is&#xD;
      advanced to override atrial septum (proximal balloon within guidecatheter and distal balloon&#xD;
      in left atrium). During balloon-dilation, the guidecatheter and balloon is advanced gently&#xD;
      into left atrium as a unit over the fixed microguidewire.&#xD;
&#xD;
      The study is conducted to evaluate the feasibility and safety of transcatheter microguidewire&#xD;
      drilling (TMD) for transseptal left atrial access.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 4, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>1 Day of procedure</time_frame>
    <description>Number of participants with successful transseptal left atrial access</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transseptal Access Procedure Time</measure>
    <time_frame>1 Day of procedure</time_frame>
    <description>Total amount of procedure time, from the beginning of the transseptal procedure until left atrium access is obtained in each patient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Heart Diseases</condition>
  <condition>Atrial Septal Dilatation</condition>
  <arm_group>
    <arm_group_label>Transcatheter microguidewire drilling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Through femoral vein, 6F MP1 guidecatheter was introduced into right atrium and engaged on fossa ovalis. Through guidecatheter, the hard &quot;back-end&quot; of microguidewire (0.014-inch BMW; Abbott, Plymouth, Minnesota, USA) was advanced to drill through fossa ovalis in the aid of a balloon (3.0 mm×15 mm; NC TREK, Abbott, Plymouth, Minnesota, USA). Over the fixed guidewire, the balloon crossed and overrode atrial septum with proximal portion in guidecatheter-tip, and the guidecatheter was advanced gently to slip into left atrium during balloon dilation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter microguidewire drilling</intervention_name>
    <description>Transcatheter microguidewire drilling with microguidewire (0.014-inch BMW; Abbott, Plymouth, Minnesota, USA), 3.0 mm×15 mm balloon (NC TREK, Abbott, Plymouth, Minnesota, USA) and 6F MP1 guidecatheter .</description>
    <arm_group_label>Transcatheter microguidewire drilling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing radiofrequency ablation within the left atrium through a&#xD;
             transseptal approach&#xD;
&#xD;
          2. Patients undergoing percutaneous balloon mitral valvuloplasty (PBMV) within the left&#xD;
             atrium through a transseptal approach&#xD;
&#xD;
          3. Patients undergoing atrial septostomy for severe pulmonary arterial hypertension or&#xD;
             heart failure&#xD;
&#xD;
          4. Patients undergoing the closure of PFO with long-tunnel through a transseptal approach&#xD;
&#xD;
          5. Patients undergoing left atrial appendage occlusion within the left atrium through a&#xD;
             transseptal approach&#xD;
&#xD;
          6. Patients undergoing the closure of peri-valvular leak in prosthetic mitral valve&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute infection or sepsis&#xD;
&#xD;
          2. Intra-cardiac thrombus&#xD;
&#xD;
          3. Associated ASD or PFO with no long-tunnel&#xD;
&#xD;
          4. Thromboembolic events within the last 6 months&#xD;
&#xD;
          5. Patients unable to grant informed, written consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaowu Yan, PhD and MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chaowu Yan, PhD and MD</last_name>
    <phone>+861088398408</phone>
    <email>chaowuyan@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shiguo Li, PhD and MD</last_name>
    <phone>+861088398408</phone>
    <email>sgli2000@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences,Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaowu Yan, PhD and MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yan Chaowu</name>
      <address>
        <city>Beijing</city>
        <state>Select A State Or Province</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaowu Yan, PhD and MD</last_name>
      <phone>+861088398408</phone>
      <email>chaowuyan@163.com</email>
    </contact>
    <investigator>
      <last_name>Chaowu Yan, PhD and MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 20, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transseptal</keyword>
  <keyword>puncture</keyword>
  <keyword>microguidewire</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

